|
[1]
|
The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) — China, 2020. China CDC Wkly 2020;2(8):113 − 22. http://dx.doi.org/10.46234/ccdcw2020.032CrossRef
|
|
[2]
|
Ma Y, Zhu DS, Chen RB, Shi NN, Liu SH, Fan YP, et al. Association of overlapped and un-overlapped comorbidities with COVID-19 severity and treatment outcomes: a retrospective cohort study from nine provinces in China. Biomed Environ Sci 2020;33(12):893 − 905. http://dx.doi.org/10.3967/bes2020.123CrossRef
|
|
[3]
|
Zhang XN, Tan Y, Ling Y, Lu G, Liu F, Yi ZG, et al. Viral and host factors related to the clinical outcome of COVID-19. Nature 2020;583(7816):437 − 40. http://dx.doi.org/10.1038/s41586-020-2355-0CrossRef
|
|
[4]
|
Barnes BJ, Adrover JM, Baxter-Stoltzfus A, Borczuk A, Cools-Lartigue J, Crawford JM, et al. Targeting potential drivers of COVID-19: neutrophil extracellular traps. J Exp Med 2020;217(6):e20200652. http://dx.doi.org/10.1084/jem.20200652CrossRef
|
|
[5]
|
Zhang Y, Xiao M, Zhang SL, Xia P, Cao W, Jiang W, et al. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N Engl J Med 2020;382(17):e38. http://dx.doi.org/10.1056/NEJMc2007575CrossRef
|
|
[6]
|
Diem S, Schmid S, Krapf M, Flatz L, Born D, Jochum W, et al. Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer 2017;111:176 − 81. http://dx.doi.org/10.1016/j.lungcan.2017.07.024CrossRef
|
|
[7]
|
Kurtul A, Ornek E. Platelet to lymphocyte ratio in cardiovascular diseases: a systematic review. Angiology 2019;70(9):802 − 18. http://dx.doi.org/10.1177/0003319719845186CrossRef
|
|
[8]
|
Balta S, Ozturk C. The platelet-lymphocyte ratio: a simple, inexpensive and rapid prognostic marker for cardiovascular events. Platelets 2015;26(7):680 − 1. http://dx.doi.org/10.3109/09537104.2014.979340CrossRef
|